In 2022, 27 European Union/European Economic Area (EU/EEA) countries reported 731 echinococcosis cases. Of these, 299 (41%) cases were reported as Echinococcus granulosus sensu lato, 185 (25%) as E. multilocularis and 247 (34%) as an unknown species.
Recent ECDC data show that despite progress in prevention and control efforts, the hepatitis B and hepatitis C viruses (HBV and HCV) continue to pose significant public health challenges in the European Union and European Economic Area (EU/EEA).
Prevalence data from sources such as population surveys can be a useful complement to case based surveillance data for hepatitis C. Case-based surveillance has limitations as most diagnosed cases are chronic in nature and detection of cases depends largely on testing practices. Prevalence data can therefore contribute towards a fuller understanding of the epidemiology of hepatitis C.
Prevalence data from sources such as population surveys can be a useful complement to case based surveillance data for hepatitis B. Case-based surveillance has limitations as most diagnosed cases are chronic in nature and detection of cases depends largely on testing practices. Prevalence data can therefore contribute towards a fuller understanding of the epidemiology of hepatitis B.
Since April 2023, over 300 shigellosis cases, many with multidrug-resistant Shigella sonnei -infections, have been reported to the European Centre for Disease Prevention and Control (ECDC).
Viral hepatitis is an inflammation of the liver caused by a virus. The most common hepatitis viruses in Europe are types A, B, and C (commonly referred to as HAV, HBV and HCV).
ECDC provides support to EU/EEA countries in monitoring their progress towards the hepatitis elimination targets and has just published a report based on the second data collection.